A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

Study Summary

To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors * To evaluate the safety and tolerability of naporafenib administered with trametinib in patients with RAS Q61X solid tumors * To characterize the pharmacokinetic (PK) profile of naporafenib and trametinib when administered to patients with RAS Q61X solid tumors

Conditions

Advanced or Metastatic Solid Tumors

Interventions / Drugs

Naporafenib Trametinib

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment86 participants

Primary Completion—

Lead SponsorErasca, Inc.

Data Retrieved2026-04-11 04:13:01.654272+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.